

REMARKS

A. Status of the claims

Claims 1, 4-6 and 8-9 have are amended, claims 2-3, 7, and 11-20 are canceled and new claims 21-23 have been added. Thus, claims 1, 4-6, 8-10 and 21-23 are currently pending. Amendments to claims 1, 4-6 and 9 are to improve clarity and do not alter the scope of the claims. Amendment to claim 8 are to improve clarity and to remove a non-essential element from the claim (*i.e.*, defining the anti-5T4 antibody as “labeled”). Support for new claims 21-22 can be found at least in claim 8. Support for new claim 23 can be found at least on page 22, lines 6-15 of the specification. No new matter has been added. Applicants reserve the right to pursue the subject matter of any claims amended or canceled herein a future continuation application.

B. Response to Office Action and to the Examiner’s Proposed Amendments

In the November 13, 2008 Office Action, the Examiner rejected all claims under 35 U.S.C. §112 as allegedly being indefinite and/or lacking enablement. Moreover, the Examiner provided a set of proposed amendments to claims 1, 4, 8 and 9 that she indicated would overcome the pending rejections under 35 U.S.C. §112. The amendments provided herein by Applicants incorporate aspects of the claims proposed by the Examiner in the Office Action (and in the facsimile dated October 21, 2008). Thus, Applicants believe that the rejections under 35 U.S.C. §112 (first and second paragraphs) are now overcome.

C. Conclusion

In view of the above arguments, Applicants believe the pending application is in condition for allowance. The Examiner is invited to contact David Gass or the undersigned with any questions or concerns.

Dated: February 13, 2009

Respectfully submitted,

By 

Marshall P. Byrd

Registration No.: 62,454

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicant